Meeting
2024 ASCO Annual Meeting
High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.
Authors
Haiyang Chen
The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, China
Haiyang Chen , Lili Wang , Yingxi Wu , Yufeng Wu , Shuxiang Ma , Sen Yang , Zhen He , Yuqing Mo , Cuicui Zhang , Qiming Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
ChiCTR2300072092
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8587)
DOI
10.1200/JCO.2024.42.16_suppl.8587
Abstract #
8587
Poster Bd #
451
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.
First Author: Gongyan Chen
Poster
2021 ASCO Annual Meeting
Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).
First Author: Chao Lyu
Poster
2021 ASCO Annual Meeting
Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.
First Author: Bianca van Veggel
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study.
First Author: Yuankai Shi